Goldman Sachs’s Polaryx Therapeutics Inc PLYX Stock Holding History

Goldman Sachs’s Portfolio PLYX Stock Details PLYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,483	Closed	-$102K	–	7205
2026 Q1	$102K	Buy	+13,483	New	+$87.1K	﹤0.01%	6209

Other funds holding PLYX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Vanguard Global Advisers Malvern, Pennsylvania $215B AUM

Goldman Sachs's PLYX Position: Q2 2026 in Review

Goldman Sachs sold out of Polaryx Therapeutics Inc (PLYX) in Q2 2026, closing a stake of 13,483 shares — an estimated $102K sold.

Goldman Sachs first reported a position in PLYX in Q1 2026 and held it in 1 quarter. The position peaked at $102K in Q1 2026. 13 funds tracked by Wall St. Rank hold PLYX as of Q2 2026.

Goldman Sachs reported no remaining Polaryx Therapeutics Inc position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 13,483 Polaryx Therapeutics Inc shares in Q2 2026, an estimated $102K.
Goldman Sachs first reported a position in Polaryx Therapeutics Inc in Q1 2026 and held it in 1 quarter.
Goldman Sachs's Polaryx Therapeutics Inc position peaked at $102K in Q1 2026.
13 funds tracked by Wall St. Rank held Polaryx Therapeutics Inc as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.